PHILADELPHIA and VANCOUVER, British Columbia — August 26, 2025 — Leads & Copy — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) announced the publication of the mechanism of action of its next generation personalized off-the-shelf immunotherapy. Research, conducted with the National Cancer Institute (NCI), has been published at JCI Insight.
The study demonstrated that semi-allogeneic dendritic-cell vaccines recruit alloreactive CD4⁺ T-cell help through mismatched MHC class II molecules, which in turn strengthens antigen-specific CD8⁺ T-cell responses against tumors, according to Jay A. Berzofsky, MD, PhD, Senior Investigator of NCI and coauthor of the publication.
Miguel Lopez-Lago, PhD, BriaCell’s Chief Scientific Officer, noted that the publication validates the core design principle behind Bria-OTS+: partial HLA matching enables effective tumor-antigen presentation, while planned HLA mismatching drives robust CD4⁺ helper responses.
Dr. William V. Williams, BriaCell’s President and CEO, added that the data are consistent with encouraging clinical results reported in the Phase 1/2a study in metastatic breast cancer.
Bria-OTS is a next generation, off-the-shelf personalized immunotherapy based on BriaCell’s lead candidate Bria-IMT currently being evaluated in a Phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer.
William V. Williams, MD, President & CEO, 1-888-485-6340, info@briacell.com
Investor Relations Contact: investors@briacell.com
Safe Harbor: This press release contains forward-looking statements that are subject to risks and uncertainties.
Source: BriaCell Therapeutics Corp.
